BIOCARTIS UPSIZES ITS EQUITY PLACEMENT DUE TO SIGNIFICANT DEMAND
Mechelen, Belgium, 23 January 2019 - Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces that due to significant demand from investors it has decided to upsize the amount of its previously announced equity offering (the "Offering") from EUR 45 million to approximately EUR 55 million. The Offering is organised as a private placement via an accelerated bookbuild offering.
Biocartis currently envisages using the net proceeds to fund the expansion of the Idylla(TM) test menu and applications, its sales and marketing activities, further investments in its cartridge manufacturing capacity, and for working capital and other general corporate purposes.
The accelerated bookbuilding procedure has commenced earlier today. The Company will announce the results of the Offering as soon as possible after closing of the bookbuilding in a subsequent press release.
Trading in Biocartis shares on Euronext Brussels is suspended during the bookbuilding period. Trading in the stock is expected to resume following the publication of the results of the Offering.
Joh. Berenberg, Gossler & Co. KG ("Berenberg"), KBC Securities SA/NV ("KBC Securities") and Kempen & Co N.V. ("Kempen") are acting as Joint Bookrunners in the Offering.
In relation to the Offering, the Company has agreed with the Joint Bookrunners to a market customary 90 days standstill period on future share issuances, waivable by the Joint Bookrunners subject to customary exceptions.